[HTML][HTML] Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco, A Botticelli… - European journal of …, 2019 - Elsevier
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco… - European journal …, 2019 - pubmed.ncbi.nlm.nih.gov
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
A Rossi, M Roberto, M Panebianco… - European Journal of …, 2019 - europepmc.org
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …
[PDF][PDF] Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco, A Botticelli… - European Journal of …, 2019 - core.ac.uk
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
[PDF][PDF] Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco… - European Journal …, 2019 - openaccessrepository.it
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
[PDF][PDF] Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco… - European Journal of …, 2019 - researchgate.net
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …
[引用][C] Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco, A Botticelli… - European Journal of …, 2019 - cir.nii.ac.jp
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and
promising targeted agents | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
promising targeted agents | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco… - EUROPEAN …, 2019 - iris.uniroma1.it
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
A Rossi, M Roberto, M Panebianco… - EUROPEAN …, 2019 - iris.uniroma1.it
Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …
in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) …